Seng-Lai “Thomas” Tan, Ph.D., is the Chief Scientific Officer at Immunitas. Thomas brings over 20 years of therapeutic research experience in both large and small biopharmaceutical settings across different disease areas, including infectious disease, autoimmunity, and oncology. He also has broad expertise in various modalities spanning small molecules, monoclonal and bispecific antibodies, and cell-penetrating peptides. Prior to joining Immunitas, Thomas served as Chief Scientific Officer at Bicara Therapeutics. Previously, he was Vice President, Head of Immunology at Elstar Therapeutics, now Marengo Therapeutics, where he devised and implemented effective strategies to build a portfolio of differentiated and high value projects in immune-oncology. He also has led several projects toward discovery and clinical development at Forma Therapeutics and EMD Serono Research and Development Institute. Dr. Tan holds a doctorate in microbiology (viral immunology) from the University of Washington School of Medicine.